Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: response to HLH-04 treatment protocol  by Jiménez-Hernández, Elva et al.
BC
E
l
p
E
M
P
a
I
b
F
R
A
2
tol Med Hosp Infant Mex. 2016;73(1):26--30
Boletín Médico del
Hospital Infantil de México (English Edition)
www.elsevier.es/bmhim
LINICAL CASE
pstein-Barr virus-associated hemophagocytic
ymphohistiocytosis: response to HLH-04 treatment
rotocol
lva Jiménez-Hernándeza, Octavio Martínez-Villegasa, Berenice Sánchez-Jaraa,
aría Angélica Martínez-Martell a, Beatriz Hernández-Sáncheza,
aloma del Rocío Loza-Santiaguilloa, Eduardo Pedro-Matíasa, José Arellano-Galindob,∗
Servicio de Hematología Pediátrica, Unidad Médica de Alta Especialidad, Hospital General, Centro Médico Nacional La Raza,
nstituto Mexicano del Seguro Social, México, D.F., México
Laboratorio de Microbiología y Enfermedades Infecciosas, Departamento de Infectología, Hospital Infantil de México
ederico Gómez, México, D.F., México
eceived 30 November 2015; accepted 3 December 2015
vailable online 28 February 2016
KEYWORDS
Hemophagocytic
lymphohistiocytosis;
Hemophagocytic
syndrome;
Epstein-Barr virus;
Protocol HLH-04
Abstract
Introduction: Hemophagocytic syndrome, macrophage activation syndrome, reactive histiocy-
tosis or hemophagocytic lymphohistiocytosis (HLH) represent a group of diseases whose common
thread is reactive or neoplastic mononuclear phagocytic system cells and dendritic cell prolif-
eration.
Clinical case: We present a case of an HLH probably associated with Epstein-Barr virus (EBV) in a
4-year-old male patient treated with HLH-04 protocol. Viral etiology in HLH is well accepted. In
this case, clinical picture of HLH was assumed secondary to EBV infection because IgM serology
at the time of clinical presentation was the only positive factor in the viral panel.
Conclusions: Diagnosis of HLH is the critical ﬁrst step to successful treatment. The earlier it is
identiﬁed, the less the tissue damage and reduced risk of multiple organ failure, which favors
treatment response.
© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail address: jose.arellano@salud.gob.mx (J. Arellano-Galindo).
444-3409/© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access article under 
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Linfohistiocitosis hemofagocítica asociada con el virus de Epstein-Barr: respuesta al
tratamiento con el protocolo HLH-04
Resumen
Introducción: El síndrome hemofagocítico, síndrome de activación de macrófagos, histiocitosis
reactiva o linfohistiocitosis hemofagocítica (HLH) representan un grupo de enfermedades cuyo
factor común es la proliferación reactiva o neoplásica de las células mononucleares fagocíticas
y del sistema de células dendríticas.
Caso clínico: Se presenta un caso de HLH sugestivo de tener una asociación con el virus del
Epstein Barr (VEB) de un paciente masculino de 4 an˜os de edad, tratado con el protocolo HLH-
04. La etiología viral en HLH es reconocida. En este caso se asumió un cuadro de HLH secundario
a una infección por VEB, ya que la serología de IgM en el momento de la presentación clínica
fue la única positiva en el panel viral.
Conclusiones: El diagnóstico de la HLH es el primer paso crítico para el éxito del tratamiento.
Entre más temprano se identiﬁque, existe menor dan˜o tisular y menor riesgo de falla orgánica
múltiple, lo que favorece la respuesta al tratamiento.
© 2016 Hospital Infantil de México Federico Gómez. Publicado por Masson Doyma México S.A.
Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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9  1. Introduction
Hemophagocytic syndrome, also known as macrophage acti-
vation syndrome, reactive histiocytosis or hemophagocytic
lymphohistiocytosis (HLH), represents a group of diseases
whose common factor is reactive or neoplastic prolifera-
tion of phagocytic mononuclear cells and of the dendritic
cell system.1 The International Histiocytosis Society coined
the term to refer to a genetic disease with severe systemic
inﬂammation,2 which occurs as the result of a recessive
genetic disorder associated with either defects in perforin
or chromosome X-linked. The disease affects the communi-
cation of the innate and adaptive immune response, causing
a lack of removal of the inﬂammatory cells harmful to
the body and that should be removed once the inﬂamma-
tory process has concluded. It is estimated that there are
∼1.2 cases per million/year. These are uncommon cases,
but its diagnosis is important because the clinical pictures
are very aggressive and evolve in a fulminant manner and
with multiple organ failure if a precise and timely diagno-
sis is not carried out.3 In this disease, T and B lymphocyte
count and circulating monocytes show normal values. How-
ever, the defect is found in the function of T-lymphocytes
and natural killer cells (NK) as well as in the activation of
CD4 + and CD8 +T lymphocytes.4 Other altered functions are
the response of lymphocytes to mitogen activation, oxida-
tion of glucose in phagocytes and, in some cases, decrease
of IgA5 antibodies. Clinical onset may be spontaneous. Prior
reports described that ∼17% of the cases are associated with
viral infections, among these, the Epstein-Barr (EBV) virus.6
This report presents a case of HLH suggested to be associated
with EBV.2. Clinical case
We present the case of a 4-year-old male patient. The
patient’s mother was 33 years of age, healthy and denied
e
n
p
dny drug addictions. The father was 35 years of age with
secondary school education. He was apparently healthy
nd admitted occasional smoking. There is an apparently
ealthy 11-year-old brother. The patient is originally from
nd resident of Ecatepec, State of Mexico. The family lives
n their own home with all urban services. Overcrowd-
ng or coexistence with animals was denied. The patient
emonstrated adequate hygiene and dietary habits. Vacci-
ation schedule was incomplete because there was a lack of
PT booster vaccine. The patient showed appropriate psy-
homotor development although he did not attend any child
evelopment center (Centro de Desarrollo Infantil, CENDI).
he patient was the product of a GII with regular prenatal
ontrol and the mother received iron and folic acid intake
rom the ﬁrst trimester without complications. The patient
as born by cesarean section at 39 weeks of gestation due
o nuchal cord. Usual resuscitation maneuvers were carried
ut. Apgar score was 8/9. The infant cried and breathed
t birth. Birthweight was 3150 g and length was 54 cm. The
nfant was discharged without complications.
In March 2014, the patient began with right ear-
che. He was seen in consultation by a private physician. 
reatment with acetaminophen, ambroxol and amoxicillin 
as prescribed for 7 days, without improvement. He 
lso began with fever up to 38.9 ◦C. Treatment with 
rimethoprim with sulfamethoxazole was added due to 
he persistence of fever. Complete blood count was 
one. Parameters low for age were seen for hemoglobin, 
ematocrit and platelets: hemoglobin 10.5 g/dl (refer-
nce value: 11.60-15.30 g/dl), hematocrit 31.7% (reference 
alue: 35.6-46.52%), leukocytes 4,920/l (reference value: 
,290-12400/l), neutrophils 1082/l (reference value: 
83-3231/l), bands 27%, atypical lymphocytes 5%, platelets
7,000/l (reference value 147-384,000/l).7 Physical
xamination observed retroauricular and inguinal lymph 
odes, hepatosplenomegaly, and persistent fever. The 
atient was referred to hematology for study protocol with 
iagnosis of lymphoproliferative syndrome.
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hFigure  1  (A,B)  Disseminated  erythem
The  patient  was  observed  with  pallor,  adequate  hydra-
ion and  was  active,  reactive,  and  neurologically  intact
ith generalized  erythematous  violaceous  rash,  ecchymosis
t the  venopuncture  sites  (Fig.  1  A  and  1B),  congestive
ropharynx without  exudate,  and  neck  with  mobile  bilat-
ral adenomegalies  of  1.5  cm  diameter.  Pulmonary  ﬁelds
ere well  ventilated  and  he  was  tachycardic.  Abdomen
as painful  on  deep  palpation,  with  hepatomegaly  at
-5-6 cm  below  the  costal  margin  and  splenomegaly  at  6  cm
nd inguinal  regions  with  1.5  cm  mobile  adenomegalies.
enitalia were  consistent  with  age  and  gender  and  extrem-
ties were  intact  with  3-sec  capillary  reﬁll.  Bone  marrow
spirate did  not  show  the  presence  of  blasts  and  there  were
bundant histiocytes  with  hemophagocytosis  (Fig.  2).
The  following  day  the  patient  was  lethargic  with  persis-
ent fever  up  to  40 ◦C  and  data  of  multiple  organ  failure.
e subsequently  presented  respiratory  deterioration  that
arranted endotracheal  intubation  through  rapid  sequence
ntubation with  cardiac  arrest,  which  reverted  with  a  single
ycle of  compressions.  He  was  admitted  to  the  Pediatric
ntensive Care  Unit  (PICU).  The  same  day  he  began  treat-
ent protocol  HLH-04.8 Brieﬂy,  the  therapy  was  carried  out
uring the  ﬁrst  8  weeks  with  etoposide,  dexamethasone  and
yclosporin A,  without  intrathecal  chemotherapy  because
he cerebral  spinal  ﬂuid  was  acellular  and  clinically  without
eurological alterations.  He  remained  for  2  days  in  the  PICU
nd continued  being  managed  in  the  Pediatric  Hematology
c
p
r
t
igure  2  Bone  marrow  aspirate.  Hemodiluted  sample,  without  blas
istiocytes  with  hematophagocytosis  are  shown.s  violaceous  rash  and  visceromegalies.
nit  with  satisfactory  progress.  It  is  important  to  mention
hat care  support  measures  were  very  important;  among
hese, blood  components  were  all  irradiated  with  white
lood cells  reduction  ﬁlter.  Two  weeks  later  his  hemato-
ogical parameters,  liver  function  tests  and  ferritin  were
ormalized (Tables  1  and  2).  At  the  same  time  the  IgM  EBV-
ositive serology  was  conﬁrmed  with  a  viral  panel  (Table  3)
s well  as  changes  in  the  lymphocytic  subpopulations
Table 4).  He  completed  the  treatment  scheme  as  man-
ated in  the  HLH-04  protocol.7 He  is  currently  disease-free
nd is  being  followed-up  as  an  outpatient.
. Discussion
athogenesis  of  secondary  HLH  is  unclear  although  it  has
een associated  with  heterozygocity  or  gene  polymorphisms
s in  the  familial  HLH.  EBV  has  been  one  of  the  eti-
logic agents  involved.9 Clinical  manifestations  of  HLH
n this  patient  correlated  with  what  has  been  previously
eported and  are  due  to  three  main  causes:  1):  hyperac-
ivation of  the  T  CD8  +  lymphocytes  and  macrophages;  2)
roliferation, ectopic  migration  and  inﬁltration  of  these
ells in  various  organs;  and  3)  hypercytokinemia,  with
ersistently elevated  levels  of  pro-inﬂammatory  cytokines
esulting in  progressive  organ  failure  which  can  lead
o death.9 These  interrelated  factors  lead  to  clinical
ts,  without  foreign  cells  and  with  activated  lymphocytes.  Some
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Table  1  Hematologic  parameters,  hepatic  function  and  ferritin.
Date  Hb  (g/dl)  Leuk/l  TL  TN  Plat/l  LDH
(IU/l)
AST
(IU/l)
ALT
(IU/l)
IB
(mg/dl)
TGL
(mg/dl)
FER
(g/l)
3/25/14  10  4,690  1,700  2,079  69,000  4,447  123  270  7  380  3,500
3/26/14  10  4,430  1,780  2,190  65,000  7,207  378  79  8  420  6,130
3/29/14  8  2,300  1,040  800  10,000  8,900  450  250  9  670  7,230
4/10/14  11  800  500  120  12,000  1,280  250  120  6  420  3,200
5/10/14  10  1,200  1,000  200  20,000  750  78  52  2  128  1,100
6/10/14  12  5,520  2,300  3,200  150,000  250  54  38  0.8  98  500
Hb, hemoglobin; Leuk, leukocytes; TL, total lymphocytes; TN, total neutrophils; Plat, platelets; LDH, lactate dehydrogenase; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; IB, indirect bilirubin; TGL, triglycerides; FER, ferritin.
Table  2  Coagulation  tests.
Date  PT  (s)  (INR*)  APTT  (s)  TT  (s)  FIB  (mg/dl)  D-D  (ng/ml)
3/26/14  18/14  (1.45)  38  25  120  1,200
3/29/14  20/14  (1.70)  46  28  80  3,200
4/10/14  16/14  (1.22)  31  20  220  500
PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; FIB, ﬁbrinogen; D-D, D-dimer; INR, internation-
alized normal ratio (reference values 0.9-1.3).
Table  3  Viral  serology  of  the  patient  at  diagnosis.
Date  HBVs  HBVc  HCV  HIV  EBV  (VCA)
IgG
EBV (VCA)
IgM
TOXO
IgG/IgM
RB
IgG/IgM
CMV
IgG/IgM
HSV  1  +  2
IgG/IgM
3/29/14  −  −  −  −  +  +  −/−  +/−  −/−  −/−
HBVs, antigen-soluble hepatitis B virus; HBVc, hepatitis B virus antigen core; HCV: hepatitis C virus; HIV, human immunodeﬁciency virus;
EBV, Epstein-Barr virus; VCA, viral capsid antigen; TOXO, toxoplasma; RB, rubeola; CMV, cytomegalovirus; HSV 1 + 2, herpes simplex virus
1 and 2.
Table  4  Subpopulations  of  lymphocytes  and  immunoglobulins.
Date  Leu/l  CD3+  CD4+  CD8+  CD4+/CD8+  NK  NKT  IgA  IgM  IgG
3/30/14  1,540  882  (66%)  454  (34%)  375  (28%)  1.2  41.53  11  193  115  630
Leu, Leucocytes; CD, cluster of differentiation; NK, natural killer; NKT, natural killer T; Ig, Immunoglobulin.
48%);
n
t
p
i
l
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p
g
c
p
sReference values: CD3 + : 900-4500 (43-76%); CD4 + : 500-2300 (23-
5-26%; IgA: 25-154; IgM: 43-196; IgG: 463-1,236.
manifestations  such  as  prolonged  fever,  lymphadenopathy,
hepatosplenomegaly,  bleeding,  skin  rash,  central  nervous
system abnormalities,  jaundice  and  laboratory  ﬁndings  of
bicytopenia or  pancytopenia,  coagulopathy,  hyperlipidemia,
hypoﬁbrinogenemia, hyperferritinemia,  transaminasemia,
hyperbilirubinemia  and  hyponatremia.9
Viral  etiology  in  HLH  is  recognized.  In  this  case  a  picture
of HLH  secondary  to  an  EBV  infection  was  assumed  because
the VCA  (viral-capsid  antigen)  serology  IgM  at  the  time
of the  clinical  presentation  was  the  only  positive  ﬁnding  in
the viral  panel.  In  addition,  there  are  results  that  place
in evidence  the  use  of  the  VCA  IgM  marker  in  patients  with
hemophagocytosis when  the  cut-off  values  of  the  test  are
10sufﬁcient to  be  considered  positive.
It  was  noted  that  15%  of  patients  with  EBV-associated
HLH develop  disorders  such  as  selective  hypogammaglobu-
linemia of  IgA  or  hyper-IgM  syndrome.  Such  syndromes  were
a
r
P
r CD8 + : 300-1600 (14-33%); CD4+/CD8 + : 0.9-2.9; NK: 3.15%; NKT:
ot  observed  in  this  patient  and,  in  fact,  the  IgA  was  noted
o be  increased.  A  more  recently  discovered  mechanism  in
atients infected  with  mycobacterium  describes  the  partic-
pation of  a  signaling  system  known  as  SLAM-SAP  (signaling
ymphocyte activation  molecule)  present  in  the  membrane
f B  and  T  lymphocytes.  SLAM-SAP  triggers  intracellular  sig-
als with  several  responses;  among  these,  a  discharge  in  IgA
roduction, such  as  might  have  been  in  this  case.11 This  work
roup previously  reported  another  case,  but  it  was  asso-
iated with  cytomegalovirus  in  a bone  marrow  transplant
atient.12
Diagnosis  of  HLH  is  the  ﬁrst  critical  step  for  treatment
uccess. The  earlier  it  is  begun,  the  less  tissue  damage
nd less  risk  of  multiple  organ  failure,  which  favors  the
esponse to  the  HLH-04  treatment.13,14 Participation  of  the
ICU and  the  supportive  care  provided  play  a  fundamental
ole.
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